Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405985 · ClinicalTrials.gov registry record · Phase 1
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
A Phase 1 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT05405985: Completed Phase 1 study, sponsored by Galderma R&D.
NCT05405985 is a Phase 1 study that has completed, run by Galderma R&D. The registered enrollment target is 192 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05405985, a Phase 1 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
Primary Outcome
Cmax was defined as the observed maximum serum concentration of nemolizumab. Cmax was used to measure the rate of absorption of nemolizumab.
Interventions
- DRUG Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 1 |
What the finished NCT05405985 record still lists
NCT05405985 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (220% higher).
The record links to 0 conditions, and to 1 intervention - of which Nemolizumab is the first listed.
NCT05405985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05405985 about?
NCT05405985 is a clinical study titled "Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe". This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
What is the current status of trial NCT05405985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-08-11. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT05405985?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT05405985?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05405985's enrollment target sits among peer trials
192 282nd of 2000 higher than 1,718 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI